A day after buzzing Hummingbird Bioscience for an antibody-drug conjugate licensing pact, Synaffix is back with a substantially similar, yet bigger deal. The Amsterdam-headquartered biotech will work with Amgen in a pact valued at up to $2 billion.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,